Related Experiment Video
Updated: Jun 14, 2026

Models of Bone Metastasis
Published on: September 4, 2012
Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease
H L Neville-Webbe1, R E Coleman
1Academic Department of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK. h.l.neville-webbe@sheffield.ac.uk
Abstract:
Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, which is increased when cancer cells invade bone. BPs are an established treatment for cancer that has spread to bone, and effectively reduce pain and other skeletal-related events. New directions in metastatic bone disease (MBD) include personalised BP therapy, such as using bone markers to guide frequency of BP administration and bone targeting agents such as denosumab (AMG 162). Clinical trials strongly suggest that denosumab might play a defined role in the future management of MBD. In terms of potential anti-cancer activity, early data tentatively suggest that zoledronic acid might have a role to play in the prevention of metastatic disease, though whether this is a direct effect on cancer cells, or indirect via the bone marrow micro-environment, or both, is as yet undiscovered. The definitive answer as to the role of adjuvant BP in early cancer is being addressed, with over 20,000 patients with breast, prostate or lung cancer currently participating in adjuvant BP randomised trials. The results of these trials should be available in the next few years, and this will establish whether BPs given early in the course of cancer will be able to prevent the formation of metastases, bone or otherwise.
Insights
Bisphosphonates (BPs) effectively treat bone metastases by inhibiting bone resorption. Ongoing trials investigate BPs for early cancer treatment to prevent metastasis formation.
Area of Science:
- Oncology
- Pharmacology
- Bone Biology
Background:
- Bisphosphonates (BPs) are crucial for managing bone metastases by inhibiting osteoclast activity.
- Cancer invasion of bone increases bone resorption, leading to pain and skeletal events.
Purpose of the Study:
- To review current and emerging bisphosphonate therapies for metastatic bone disease (MBD).
- To explore the potential anti-cancer effects of bisphosphonates beyond bone resorption inhibition.
- To highlight ongoing research into adjuvant bisphosphonate use for early-stage cancer prevention.
Main Methods:
- Review of clinical trials and emerging data on bisphosphonate use in MBD.
- Discussion of personalized bisphosphonate therapy and novel bone-targeting agents like denosumab.
- Analysis of large-scale randomized trials evaluating adjuvant bisphosphonate therapy in early cancer.
Main Results:
- Bisphosphonates are established treatments for reducing skeletal-related events in MBD.
- Denosumab shows promise for future MBD management.
- Preliminary evidence suggests zoledronic acid may have a role in preventing cancer metastasis, though the mechanism is unclear.
Conclusions:
- Bisphosphonates are vital in managing MBD, with personalized approaches and agents like denosumab advancing care.
- Further research is needed to elucidate the direct anti-cancer effects of bisphosphonates.
- Results from large adjuvant bisphosphonate trials are anticipated to clarify their role in preventing cancer metastasis.
Related Concept Videos
Bone Remodeling
Osteoclasts in Bone Remodeling
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Urinary Tract Calculi III: Medical Management
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Drugs that Destabilize Microtubules
